Anaphore appoints Paul Grayson CEO
This article was originally published in Scrip
Anaphore has appointed Paul Grayson president and CEO, replacing Dr Katherine Bowdish, a co-founder of Anaphore, who will continue to serve the company as a consultant. Mr Grayson previously served as CEO of Fate Therapeutics, a privately held biopharmaceutical company, and founding chairman and CEO of Senomyx.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.